Neurocognitive impairment in schizophrenia and how it affects treatment options

Canadian Journal of Psychiatry

Volumn 42, Issue 3, 1997, Pages 255-264

  Bilder, Robert M ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

antipsychotic drugs; basal ganglia; clozapine; dopamine; frontal lobes; hippocampus; limbic system; neuropsychology; schizophrenia

Indexed keywords

CLOZAPINE; FANANSERIN; FLUPENTIXOL; HALOPERIDOL; ILOPERIDONE; MAZAPERTINE; NEUROLEPTIC AGENT; OLANZAPINE; PRAMIPEXOLE; QUETIAPINE; SERTINDOLE; UNCLASSIFIED DRUG; ZIPRASIDONE;

COGNITIVE DEFECT; HUMAN; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA;

EID: 0030944708     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379704200303     Document Type: Review

References (58)

1. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993:54:13-7.
2. Lieberman JA, Sobel SN. Predictors of treatment response and course of schizophrenia. Current Opinion in Psychiatry 1993;6:63-9.
3. Lieberman JA, Koreen A, Chakos M, Sheitman B, Woemer M, Alvir JMA, Bilder RM. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57:5-9.
4. Bilder RM, Bates J. Neuropsychological prediction of neuroleptic treatment response. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia-concepts and methods. New York: Springer-Verlag; 1994. p 99-110.
5. Jaeger J, Berns S, Tigner A, Douglas E. Remediation of neuropsychological deficits in psychiatric populations: rationale and methodological considerations. Psychopharmacol Bull 1992;28:367-90.
6. Kern RS, Green MF, Satz P. Neuropsychological predictors of skills training for chronic psychiatric patients. Psychiatry Res 1992;43:223-30.
7. Green MF. Cognitive remediation in schizophrenia: is it time yet? Am J Psychiatry 1993;150:178-87.
8. Mueser KT, Bellack AS, Douglas MS, Wade JH. Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology. Psychiatry Res 1991;37:281-96.
9. Heaton RK, Crowley TJ. Effects of psychiatric disorders and their somatic treatment on neuropsychological test results. In: Filskov SB, Boll TJ, editors. Handbook of clinical neuropsychology. New York: J Wiley; 1981. p 481-525.
10. Bilder RM. Structure-function relations in schizophrenia: brain morphology and neuropsychology. In: Walker EF, Dworkin RH, Cornblatt BA, editors. Progress in experimental personality and psychopathology research, volume 15. New York: Springer; 1992. p 183-251.
11. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first episode and chronic schizophrenia: evidence for progressive deterioration? Schizophr Bull 1992;18:437-48.
12. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 1992;28:353-66.
13. Blanchard JJ, Neale JM. The neuropsychological signature of schizophrenia: generalized or differential deficit? Am J Psychiatry 1994;151:40-8.
14. Braff DL, Heaton RK, Kuck J,Cullum M, Moranville JT, Grant I, Zisook S. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card SortingTest results. Arch Gen Psychiatry 1991;48:891-8.
15. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992;49:195-205.
16. Javitt DC, Doneshka P, Grochowski S, Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry 1995;52:550-8.
17. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, and others. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-24.
18. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, and others. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-31.
19. Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, and others. Anterior hippocampal volume reductions predict "frontal lobe" dysfunction in first episode schizophrenia. Schizophr Res 1995;17:47-58.
20. Gruzelier JH, Seymour K, Wilson L, Jolley A, Hirsch SR. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988;45:623-9.
21. Gur RE, Gur RC, Saykin AJ. Neurobehavioral studies in schizophrenia: implications for regional brain dysfunction. Schizophr Bull 1990;16:445-51.
22. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first episode schizophreniform patients. Am J Psychiatry J 1992;149:898-903.
23. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984;10:160-202.
24. Nuechterlein KN, Dawson ME, Green MF. Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia. Acta Psychiatr Scand l994;384:7l-9.
25. Goldberg TE, Weinberger DR, Berman KF, Pliskin NH, Podd MH. Further evidence for dementia of the prefrontal type in schizophrenia. Arch Gen Psychiatry 1987;44;1008-14.
26. Robbins TW, The case of frontostriatal dysfunction in schizophrenia. Schizophr Bull 1990;16:391-402.
27. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139-54.
28. Bilder RM, Degreef G. Morphologic markers of neurodevelopmental paths to schizophrenia. In: Mednick SA, Cannon TD, Barr CE, LaFosse JM, editors. Developmental neuropathology of schizophrenia. New York: Plenum; 1991. p 167-90.
29. Bilder RM, Szeszko PR. Structural neuroimaging and neuropsychological impairments. In: Pantelis C, Nelson HE, Barnes TRE, editors. The neuropsychology of schizophrenia. New York: J Wiley; 1996. p 279-98.
30. Flor-Henry P. Cerebral basis of psychopathology. Boston: John Wright; 1983.
31. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992;149:890-7.
32. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD. The neuropsychology of schizophrenia. Behavioral and Brain Sciences 1991;14:1-84.
33. Frith CD. The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med 1987;17:631-48.
34. Frith CD, Done DJ. Towards a neuropsychology of schizophrenia. Br J Psychiatry 1988:153:437-43.
35. Frith CD, Done DJ. Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action. Psychol Med 1989;19:359-63.
36. Frith CD, Friston K, Liddle PF, Frackowiak RS. Willed action and the prefrontal cortex in man: a study with PET. Proc R Soc Lond B Brol Sci 1991;244:241-6.
37. Heresco-Levy U, Silipo G, Javitt DC. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996;32:731-40.
38. Deutch A. Clozapine effects on fos expression in prefrontal cortex and paraventricular thalamic nuclei. Neuroscience 1996;70:377-89.
39. May PRA, Van Putten T, Yale C, Potepan P, Jenden DJ, Fairchild MD, and others. Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis 1976;162:177-83.
40. Blanchard JJ, Neale JM. Medication effects: conceptual and methodological issues in schizophrenia research. Clin Psychol Rev 1992;12:345-61.
41. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics. effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990;16:477-99.
42. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Archives of Clinical Neuropsychology 1988;3:249-71.
43. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98:367-80.
44. Frith CD. Schizophrenia, memory, and anticholinergic drugs. J Abnorm Psychol 1984;93:339-41.
45. Seidman LJ, Pepple JR, Faraone SV, Kremen WS, Green AI, Brown WA, and others. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993;33:575-84.
46. Classen W, Laux G. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry 1988;21:295-7.
47. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
48. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, and others. The impact of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-8.
49. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-25.
50. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55 Suppl B:82S-87S.
51. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, and others. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996;15:361-9.
52. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991;251:947-50.
53. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-8.
54. Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry 1994;55 Suppl B:43S-46S.
55. Wyatt RJ. Risks of withdrawing antipsychotic medication. Arch Gen Psychiatry 1995;52:205-8.
56. Dolan RJ, Grasby PM. Exploring the functional role of monoaminergic neurotransmission: a method for exploring neurotransmitter dysfunction in psychiatric disorders [editorial]. Br J Psychiatry 1994;164:575-80.
57. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1995;378:180-2.
58. Friston KJ, Grasby PM, Bench CJ, Frith CD, Cowen PJ, Liddle PF, and others. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci Lett 1992;141:106-10.